Description
What this story covers
Solventum's Q3 2025 10-Q highlights a 4 billion dollar Purification sale yielding 1 point 5 billion dollar gain, boosting net income to 1 point 27 billion dollars. Core sales grew modestly at 2 point 4 percent year-to-date, with focus on MedSurg, Dental, and Health IT segments. Debt reduced, liquidity strong for 500 million dollar savings initiative amid stable risks.
Story snapshot
CompanySolventum Corporation
TickerSOLV
VariantStandard detailed
Duration13:46
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001964738-25-000091
Full Story Script
Content not available for this story.
